Tumor response to treatment (per investigator assessment)
| No of patients (%) with respective assessment | Overall | Group 4: | Group 5 ICB-experienced patients | ||
| N=221 | UBC N=40 | MEL N=18 | NSCLC* N=40 | UBC N=12 | |
| Complete response (CR) | 3 (1.4)† | 1 (2.5) | 0 | 0 | 0 |
| Partial response (PR) | 14 (6.4)† | 3 (7.5) | 1 (5.6) | 5 (12.5) | 1 (8.3) |
| Stable disease | 78 (35.5) | 16 (40.0) | 8 (44.4) | 14 (35.0) | 4 (33.3) |
| Progressive disease | 102 (46.4) | 18 (45.0) | 7 (38.9) | 20 (50.0) | 6 (50.0) |
| Missing or unevaluable‡ | 23 (10.5) | 2 (5.0) | 2 (11.1) | 1 (2.5) | 1 (8.3) |
| Objective response rate | 17 (7.7) | 4 (10.0) | 1 (5.6) | 5 (12.5) | 1 (8.3) |
| Disease control rate | 95 (43.2) | 20 (50.0) | 9 (50.0) | 19 (47.5) | 5 (41.7) |
Investigator-based RECIST assessment
*Histology was: 31 patients (77.5%) with adenocarcinoma, 7 patients (17.5%) with squamous carcinoma and 1 (2.5%) each with an undifferentiated or unspecified carcinoma.
†Two additional patients experienced pseudoprogression but turned into responders afterwards with a PR and CR, respectively.
‡Patients were classified as missing or unevaluable if no post-baseline response assessments were available or all postbaseline response assessments were unevaluable.
ICB, immune checkpoint blocker; MEL, melanoma; N, number of patients; NSCLC, non-small cell lung cancer; UBC, urothelial bladder cancer.